BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2021 Earnings Results

Biocryst Pharmaceuticals Misses on EPS — Stock Down 18.1%

The earnings report indicates that Biocryst Pharmaceuticals is facing challenges, particularly reflected in its EPS miss. The stock's significant drop of 18.1% suggests investor disappointment and concern over the company's current trajectory. Without guidance, uncertainty remains about the company's future performance and strategy.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.33	N/A	-8.55%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over current performance but remains focused on future developments. They did not provide specific guidance for upcoming quarters.

Management acknowledged challenges in meeting expectations.

They emphasized ongoing efforts to improve product pipeline.

Biocryst Pharmaceuticals Misses on EPS — Stock Down 18.1%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

Biocryst Pharmaceuticals Misses on EPS — Stock Down 18.1%

Key numbers

Management commentary